Opinion|Videos|January 31, 2025
Key Highlights: CEPHEUS Trial SubQ Dara-VRd vs VRd in Transplant-Eligible or Transplant-Deferred NDMM
Panelists discuss how the CEPHEUS study comparing subcutaneous daratumumab plus VRd vs VRd alone in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) provides important insights into the role of quadruplet therapy in this specific population.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Let’s transition to patients with NDMM who are considered transplant ineligible or transplant deferred.
- Can you summarize the recent data from the CEPHEUS study evaluating subcutaneous daratumumab plus VRd vs VRd in transplant-ineligible NDMM?
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
The FDA’s decision on iberdomide is a “landmark approval” for those with multiple myeloma, according to Surbhi Sidana, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
2
Fixed-Duration Combinations and MRD-Guided Therapy as Emerging Priorities in CLL
3
Japan Approves T-DXd Combo and Dato-DXd for First-Line Metastatic Breast Cancer
4
NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma
5